

Indian retail participation on the NSE has expanded from roughly 3 crore unique investors in 2019 to more than 11 crore in 2026 — a 3.6x explosion in less than seven years. Yet a SEBI study has repeatedly shown that 93% of individual traders in the equity Futures & Options segment incur net losses. The single biggest behavioural reason: investors look at the share price first and the financial statements last (if at all). Even those who do glance at the financials usually stop at revenue, profit, and the P/E ratio — almost no one reads Note 3 (Property, Plant & Equipment) of the Annual Report. And that is precisely where one of the most under-appreciated quality markers in Indian small- and mid-caps hides — the Depreciation-to-Gross-Block Ratio.
This single ratio, computed in 30 seconds from the audited financials, tells you (a) how new the company’s productive asset base is, (b) the implied average useful life of those assets, (c) whether management is over-stating or under-stating reported profits through depreciation choices, and (d) how soon the company will need a fresh capex round just to maintain its current revenue. Combined with the Capex-to-Depreciation ratio and CWIP-to-Gross-Block, it forms the three-legged stool of asset-base diagnostics — the same stool any forensic accountant uses to test whether a company’s reported earnings are durable.
Table of Contents
ToggleEvery Indian listed company that owns tangible fixed assets — factories, plant & machinery, buildings, vehicles, office equipment, computers — must disclose two numbers in its Property, Plant & Equipment schedule under Schedule III of the Companies Act, 2013, read with Indian Accounting Standard (Ind AS) 16:
The Depreciation-to-Gross-Block ratio is simply:
Depreciation-to-Gross-Block Ratio = (Depreciation Charge for the Year ÷ Gross Block at Year-End) × 100
The reciprocal of this ratio — 1 ÷ (Dep/GB) — gives you the implied weighted-average useful life of the company’s tangible asset base, expressed in years. So a Dep/GB of 7% implies an asset base that is being depreciated over a weighted-average life of roughly 14 years, which is broadly consistent with the typical useful-life schedule in Schedule II of the Companies Act, 2013, for plant & machinery (15 years), buildings (30 years), and electrical equipment (10 years).
In any Indian Annual Report you will find:

Across most Indian manufacturing and specialty-chemicals businesses, the Dep/GB ratio typically falls in three diagnostic buckets:
Imagine a hypothetical specialty-chemicals company “Compounder Co.” with these audited markers in a recent year:
This profile tells a story of orderly compounding: the asset base is neither artificially young nor stretched, the company is reinvesting at well above the depreciation rate (so the productive base is growing), the CWIP pipeline points to incremental revenue 12–24 months out, and the balance sheet can fund the capex without bank loans. The 8% Dep/GB is not “good” or “bad” in isolation — it is consistent with disciplined asset management. This is the classic profile of a long-term compounder.
Now consider a historical-style profile that has surfaced repeatedly in failed Indian small-caps: a company with Dep/GB of 4% (very low — implied useful life of 25 years), no meaningful CWIP, Capex-to-Depreciation of 0.6x (i.e., reinvesting less than the rate at which assets are being consumed), accumulated depreciation now over 70% of gross block (net block is just 30% of gross block), and rising “Other Income” as a share of PBT (often from one-off sales of old assets). This combination is what forensic accountants call a “harvest mode” — the company is stretching depreciation policy to flatter the bottom line while quietly running its productive base down. The market eventually re-rates such names downward because the absent capex pipeline guarantees a future revenue stall.
Note: this red-flag illustration is intentionally generic. The point is the combination of warning signals, not the absolute Dep/GB number — a 4% ratio in a young real-estate or hotel asset is normal; in a 30-year-old chemicals plant it is a red flag.
Now let us apply the Depreciation-to-Gross-Block lens to a real, audited Indian small-cap — Titan Biotech Limited — using only its FY25 audited disclosures. This is presented purely as an educational illustration of how the ratio behaves in a disciplined manufacturer; it is not a buy/sell recommendation.
| FY25 Audited Marker | Value | What It Tells the Reader |
|---|---|---|
| Gross Block (closing) | ~₹57 Cr | Compact, focused asset base — single-site Bhiwadi facility, no asset sprawl. |
| Capital Work-in-Progress | ~₹11 Cr | ~19% of gross block — material capex pipeline being built for the next leg of growth. |
| Depreciation / Gross Block (FY25) | ~7% | Implies a weighted-average useful life of ~14 years — aligned with Schedule II for plant & machinery. |
| Total Borrowings | ₹3 Cr | Essentially debt-free — capex pipeline is being funded internally, not by leverage. |
| CFO / Operating Profit (FY25) | ~103% | Cash generation slightly exceeds operating profit — premium marker of earnings quality and depreciation realism. |
| FY25 Total Revenue | ~₹214 Cr | Asset-turnover (Revenue/Gross Block) of ~3.75x — a high asset productivity for a biotech manufacturer. |
| Contingent Liabilities | ₹7.78 Cr | Low relative to net worth — limited hidden obligations against the asset base. |
| 10-yr Revenue CAGR | ~15% | Disciplined top-line compounding on a steadily growing asset base. |
| 10-yr PAT CAGR | ~29% | Operating leverage on a compact asset base — earnings compounding faster than revenue. |
What story does this tell when read through the Depreciation-to-Gross-Block lens? First, a ~7% Dep/GB sits squarely in the Schedule II-consistent “Goldilocks zone” for an asset-heavy specialty biotech manufacturer. This rules out the two most common red flags around the ratio: it is neither artificially low (which would suggest aggressive useful-life elections to flatter profits) nor stretched (which would suggest a rapidly ageing asset base overdue for replacement). The implied ~14-year weighted-average useful life is realistic for plant & machinery used in microbial culture media, peptones, collagen and gelatin manufacturing.

Second — and this is where the ratio gets its real signal value — Dep/GB of ~7% combined with CWIP at ~19% of gross block and total borrowings of just ₹3 Cr tells the reader that the company is preparing the next leg of asset-base growth from internal accruals rather than from bank debt. A 103% CFO/OP ratio confirms that the depreciation charge is not an accounting fiction — it is being matched (and slightly exceeded) by actual operating cash conversion. Pair this with the audited ~15% 10-year revenue CAGR and ~29% 10-year PAT CAGR, and you see a textbook illustration of what a disciplined small-cap asset compounder looks like on paper. Again, this is purely educational — no valuation verdict is implied.
The Depreciation-to-Gross-Block ratio is most powerful when used as a filter rather than a single point estimate. Here is a practical four-step workflow any Indian retail investor can run in under 10 minutes per company:
Used as a four-corner cross-check, the Dep/GB ratio quietly does most of the heavy lifting that investors typically attempt with a P/E or P/B ratio — except it answers a more fundamental question: is this company even generating the cash to maintain the asset base that produced its reported profits?
Even seasoned analysts misread this ratio. The five most frequent traps are:
India’s listed manufacturing universe — small-caps especially — has a structural reason to take the Dep/GB ratio seriously. SEBI’s own finfluencer regulations (Aug 2024) and the regulator’s repeated warnings about the 93%-loss-rate in equity F&O highlight a deeper problem: the average Indian retail investor spends far more time on price-based “signals” than on the audited reality of the businesses they own. The Dep/GB ratio is one of the simplest mechanical antidotes to that imbalance — it forces the reader to engage with the actual asset base, the actual depreciation policy, and the actual capex pipeline, all of which are disclosed transparently under SEBI’s Listing Obligations and Disclosure Requirements (LODR) regulations.
For an NSE/BSE investor sifting through 5,000+ listed names, a 30-second Dep/GB read is one of the highest-signal-per-second filters available before committing further research time. Companies that fail the filter rarely come back to deliver durable returns; companies that pass it, in combination with the other quality markers covered in our earlier articles (CFO/PAT, Interest Coverage, Net Debt/EBITDA, CWIP-to-Gross-Block, RoCE), tend to cluster in the disciplined-compounder bucket.
SEBI Disclaimer: 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses according to a SEBI study. F&O trading is essentially gambling. Focus on quality stock picking and long-term value investing instead. Multibagger Securities Research & Advisory Pvt. Ltd. is a SEBI Registered Investment Advisor (INA100007736). This content is for educational purposes only and is not a buy/sell recommendation on any stock including Titan Biotech Limited (BSE: 524717).
— Manish Goel / SEBI Registered Investment Advisor (INA100007736)
